Clinical remission · people with active UC
Cannabidiol showed no clear difference in clinical remission at 10 weeks compared with placebo (low certainty).
1 finding from 1 review
CRP (mg/dL) at end of study · people with active UC
1 finding from 1 review
Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response at 10 weeks · people with active UC
Cannabidiol showed no clear difference in clinical response at 10 weeks compared with placebo (low certainty).
1 finding from 1 review
CRP (mg/dL) at end of study · people with active UC
1 finding from 1 review
IBDQ at week 6 · people with active UC
1 finding from 1 review
Adverse events · people with active UC
Cannabidiol probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with active UC
Cannabidiol showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
Cannabidiol showed no clear difference in withdrawal due to adverse event compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cancer detection · detecting colon cancer in patients with inflammatory bowel disease
It is very uncertain whether surveillance changes cancer detection compared with non surveillance (very low certainty).
1 finding from 1 review
Death from colorectal cancer · detecting colon cancer in patients with inflammatory bowel disease
It is very uncertain whether surveillance changes death from colorectal cancer compared with non surveillance (very low certainty).
1 finding from 1 review
Cancer stage‐ Duke A or B · detecting colon cancer in patients with inflammatory bowel disease
It is very uncertain whether surveillance changes cancer stage‐ Duke A or B compared with non surveillance (very low certainty).
1 finding from 1 review
Cancer stage‐ Duke C or D · detecting colon cancer in patients with inflammatory bowel disease
It is very uncertain whether surveillance changes cancer stage‐ Duke C or D compared with non surveillance (very low certainty).
1 finding from 1 review
Clinical response · Patients with collagenous colitis
It is very uncertain whether bismuth subsalicylate changes clinical response compared with placebo (very low certainty).
1 finding from 1 review
RR 10.8 [0.75, 155.93]
1 study · 9 participants
Very low
Serious adverse events · Patients with collagenous colitis
Budesonide showed no clear difference in serious adverse events compared with mesalazine (low certainty).
1 finding from 1 review